ASD Defiance Autism Impact ETF
ETFETF quote, holdings, sector allocation, technicals, and options analytics. Fibonacci levels
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
Defiance Autism Impact ETF (ASD) ETF
No description available.
- Exchange
- XNAS
- Inception
- 2026-06-01
- Has Options
- No
- Expense ratio
- 0.79% prospectus, filed May 28, 2026
- Assets
- $1.4M SEC filing, Jun 30, 2026
- Trailing yield
- 0.03% paid quarterly
- Average daily volume
- $25K 30 sessions
- Holdings
- 39 top 10 are 30.8%
- Listed
- Jun 1, 2026 Nasdaq
Stated objective. The Defiance Autism Impact ETF (the Fund or the Autism ETF) seeks to track the total return performance, before fees and expenses, of the VettaFi Autism Impact Index (the Index). (from the fund's prospectus)
All 39 holdingsFlow historySimilar fundsOverlap toolAll ESG & Values ETFs
- Jun 2026
- +$1.3M latest reported month
- Latest 3 months
- +$1.3M +92.5% of assets
- Latest 12 months
- —
View as a table
| Month | Net flow |
|---|---|
| Jun 2026 | +$1.3M |
Net creations and redemptions from the fund's SEC filings, which become public about 60 days after each quarter. Every month since 1 months ago
| Fund | Overlap | Fee | Assets | 1Y | |
|---|---|---|---|---|---|
| IXJiShares Global Healthcare ETF | 19% | 0.38% | $4.5B | +17.9% | compare |
| PPHVanEck Pharmaceutical ETF | 19% | 0.36% | $1.1B | +24.2% | compare |
| JDOCJPMorgan Healthcare Leaders ETF | 18% | 0.65% | $9.4M | +16.4% | compare |
| FTXHFirst Trust Nasdaq Pharmaceuticals ETF | 16% | 0.60% | $1.1B | +45.1% | compare |
| MEDXHorizon Kinetics Medical ETF | 16% | 0.85% | $17M | +15.1% | compare |
Ranked by how much of the two portfolios is the same securities.
- Holdings vs fair value
- +20.0% 48% under, 10% over · 54% covered
- Price / earnings
- — 33% loss-making · 54% covered
- Price / book · sales
- 2.5 · — revenue growth +7.8%
- Above 200-day average
- 55% 50% above 50-day · by weight
- Short interest
- 9.3% of float, weighted · 5.5 days to cover
- Insider buying
- 5% of weight had net insider buying, 90 days; 23% net selling
- 13F holders
- +7.1% change in shares held by institutions, latest quarter
- Reporting earnings
- 2.1% of weight in 7 days; 20.2% in 14
Each figure is the fund's holdings weighted by position size, using our data on those stocks, and covers only the share of the stock holdings stated. Positive fair value means the holdings trade below our estimate.
| Ex-Date | Pay Date | Amount | Type |
|---|---|---|---|
| 2026-09-23 | 2026-09-24 | $0.0020 | CD |
| 2026-06-24 | 2026-06-25 | $0.0060 | CD |
| Symbol | Name | Weight % | Asset Class | Country |
|---|---|---|---|---|
| DFTX | Definium Therapeutics Inc | 4.77% | Equity (common) | US |
| — | Neuren Pharmaceuticals Ltd | 3.23% | Equity (common) | AU |
| LFST | LifeStance Health Group Inc | 3.04% | Equity (common) | US |
| — | Otsuka Holdings Co Ltd | 2.95% | Equity (common) | JP |
| ACHC | Acadia Healthcare Co Inc | 2.90% | Equity (common) | US |
| ACAD | ACADIA Pharmaceuticals Inc | 2.89% | Equity (common) | US |
| MPLT | MapLight Therapeutics Inc | 2.89% | Equity (common) | US |
| ABBV | AbbVie Inc | 2.72% | Equity (common) | US |
| BTSG | BrightSpring Health Services I | 2.70% | Equity (common) | US |
| RVTY | Revvity Inc | 2.68% | Equity (common) | US |
| BFAM | Bright Horizons Family Solutio | 2.65% | Equity (common) | US |
| — | Medicover AB | 2.63% | Equity (common) | SE |
| — | Ipsen SA | 2.60% | Equity (common) | FR |
| — | Sumitomo Pharma Co Ltd | 2.60% | Equity (common) | JP |
| JNJ | Johnson & Johnson | 2.59% | Equity (common) | US |
| BWAY | Brainsway Ltd | 2.58% | Equity (common) | IL |
| — | Pearson PLC | 2.56% | Equity (common) | GB |
| AVXL | Anavex Life Sciences Corp | 2.53% | Equity (common) | US |
| — | Novartis AG | 2.53% | Equity (common) | CH |
| — | Life Healthcare Group Holdings | 2.52% | Equity (common) | ZA |
| BMRN | BioMarin Pharmaceutical Inc | 2.52% | Equity (common) | US |
| — | KPJ Healthcare Bhd | 2.51% | Equity (common) | MY |
| RGEN | Repligen Corp | 2.50% | Equity (common) | US |
| — | Roche Holding AG | 2.50% | Equity (common) | CH |
| SUPN | Supernus Pharmaceuticals Inc | 2.50% | Equity (common) | US |
| — | Jazz Pharmaceuticals PLC | 2.50% | Equity (common) | IE |
| LLY | Eli Lilly & Co | 2.49% | Equity (common) | US |
| BMY | Bristol-Myers Squibb Co | 2.47% | Equity (common) | US |
| — | GSK PLC | 2.46% | Equity (common) | GB |
| VNDA | Vanda Pharmaceuticals Inc | 2.45% | Equity (common) | US |
| GHC | Graham Holdings Co | 2.37% | Equity (common) | US |
| — | Teva Pharmaceutical Industries | 2.35% | Equity (common) | IL |
| — | Takeda Pharmaceutical Co Ltd | 2.35% | Equity (common) | JP |
| LOPE | Grand Canyon Education Inc | 2.31% | Equity (common) | US |
| — | H Lundbeck A/S | 2.29% | Equity (common) | DK |
| — | Shionogi & Co Ltd | 2.29% | Equity (common) | JP |
| PFE | Pfizer Inc | 2.25% | Equity (common) | US |
| LRN | Stride Inc | 2.12% | Equity (common) | US |
| — | First American Government Obli | 0.21% | Short-term investment | US |
| Month | '26 | Avg |
|---|---|---|
| Jan | -- | -- |
| Feb | -- | -- |
| Mar | -- | -- |
| Apr | -- | -- |
| May | -- | -- |
| Jun | 9.80% | 9.80% |
| Jul | -1.06% | -1.06% |
| Aug | 3.28% | 3.28% |
| Sep | -2.58% | -2.58% |
| Oct | 1.34%* | 1.34% |
| Nov | -- | -- |
| Dec | -- | -- |
| Total | 10.77% | 10.77% |
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
Momentum Oscillators
Volume & Volatility
Data Summary
LLM Stock Analysis Report: ASD
Executive Summary:
Overall Assessment: NEUTRAL (Confidence Level: 6/10)
Key Drivers: Recent technical signals, beta analysis, and low volatility.
Primary Risks: Overbought conditions, lack of recent news catalysts, and limited institutional interest.
Investment Thesis: ASD's short-term momentum suggests a potential pullback or consolidation phase. The stock's beta indicates low volatility relative to the market, which could support further gains. However, overbought conditions and the absence of recent news catalysts may limit upside potential in the near term.
Recent News Sentiment Impact: No recent news headlines are available for analysis.
Technical Analysis:
Trend Direction: Short-term: NEUTRAL (1-4 weeks), Medium-term: BEARISH (1-3 months)
Support/Resistance Levels: Key price levels from moving averages and technical patterns:
- SMA 20: $27.38
- EMA 12: $27.75
Momentum Signals:
- RSI interpretation: Overbought (>70), with a value of 70.08.
- MACD signal: Bullish, indicating momentum remains strong.
- Bollinger Bands position: Overbought, suggesting the stock may pull back or consolidate.
Volume Analysis: Volume trends and institutional interest signals:
- Volume SMA 20: $267.59
- On-Balance Volume (OBV): -368.28 (bearish)
- Volume Rate of Change: -31.82% (bearish)
News & Sentiment Analysis:
Recent Headlines Summary: No recent news headlines are available.
Sentiment Assessment: Neutral, as no recent news is available for analysis.
Catalyst Identification: None identified.
Market Narrative: The market's neutral sentiment and lack of catalysts may impact ASD's performance in the near term.
Risk & Volatility Assessment:
Beta Interpretation: Low volatility relative to the market (beta: 0.23).
Volatility Regime: Low volatility, with a historical volatility range of HV20 16.3% / HV30 15.9%.
Options Market Signals: No options data available for analysis.
Downside Protection: Support levels and risk management considerations:
- SMA 20: $27.38
- EMA 12: $27.75
Market Context & Positioning:
Sector Performance: Neutral, with the sector performing similarly to the market.
Institutional Activity: Limited institutional interest, as suggested by the volume analysis.
Correlation Analysis: ASD's correlation with the market is low (R-squared interpretation).
Relative Valuation: The stock trades within its recent trading range, with no significant deviation from historical levels.
Key Levels & Action Items:
Critical Price Levels: Support/resistance to monitor:
- SMA 20: $27.38
- EMA 12: $27.75
Breakout/Breakdown Levels: Technical levels that could trigger significant moves:
- Upper Bollinger Band: $28.42
- Lower Bollinger Band: $26.33
Time-Sensitive Catalysts: None identified.
Risk Management: Stop-loss levels and position sizing considerations:
- SMA 20: $27.38 (stop-loss)
- EMA 12: $27.75 (stop-loss)
By analyzing ASD's technical indicators, news sentiment, and risk metrics, we conclude that the stock is in a neutral phase, with low volatility and no recent catalysts driving its performance. The absence of significant price movements suggests a potential pullback or consolidation phase, which may be supported by overbought conditions. Investors should consider managing their exposure to ASD based on the stock's technical levels and risk metrics.
ASD Options Activity & IV Rank
Each spread is ranked by a composite score built in three stages. Full documentation →
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Enter a ticker to render the implied volatility surface.
Enter a ticker to render the implied volatility smile.
Risk Metrics
Analysis Details
Data Points: 95
Period: 252 trading days
Low volatility - stock moves less than market
ASD Institutional Ownership (13F)
Latest filings — 2026-06-30Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
| # | Filer | Notional Value | % of Total | Period |
|---|
| # | Filer | Notional Value | % of Total | Period |
|---|
Click any bar to view the full quote for that stock.
| Symbol | Name | Weight % | Price | 1 Day | 1 Week | 1 Month |
|---|---|---|---|---|---|---|
| DFTX | Definium Therapeutics Inc | 4.77% | $32.1 | -6.30% | -13.01% | -17.29% |
| LFST | LifeStance Health Group Inc | 3.04% | $11.74 | -5.09% | -5.48% | -6.60% |
| ACHC | Acadia Healthcare Co Inc | 2.90% | $29.98 | -3.41% | +2.50% | +5.82% |
| ACAD | ACADIA Pharmaceuticals Inc | 2.89% | $19.12 | -2.99% | -3.34% | -29.94% |
| MPLT | MapLight Therapeutics Inc | 2.89% | $7.7 | -3.99% | -12.80% | -29.49% |
| ABBV | AbbVie Inc | 2.72% | $285.42 | +0.71% | +3.24% | +8.13% |
| BTSG | BrightSpring Health Services I | 2.70% | $60.87 | -2.39% | -4.50% | +7.20% |
| RVTY | Revvity Inc | 2.68% | $152.64 | -1.34% | -1.00% | +6.41% |
| BFAM | Bright Horizons Family Solutio | 2.65% | $71.15 | +1.04% | +2.45% | +8.34% |
| JNJ | Johnson & Johnson | 2.59% | $255.56 | +0.90% | -2.25% | -5.34% |
| BWAY | Brainsway Ltd | 2.58% | $11.44 | -3.21% | -2.80% | -15.94% |
| AVXL | Anavex Life Sciences Corp | 2.53% | $1.31 | -11.49% | -12.08% | -45.87% |
| BMRN | BioMarin Pharmaceutical Inc | 2.52% | $54.68 | -2.44% | -0.21% | -14.48% |
| RGEN | Repligen Corp | 2.50% | $175.42 | -4.75% | +0.89% | -0.83% |
| SUPN | Supernus Pharmaceuticals Inc | 2.50% | $37.88 | -4.27% | -11.23% | -9.81% |
| LLY | Eli Lilly & Co | 2.49% | $1257.03 | +0.43% | +6.59% | +9.03% |
| BMY | Bristol-Myers Squibb Co | 2.47% | $59.75 | -1.35% | +1.07% | -5.25% |
| VNDA | Vanda Pharmaceuticals Inc | 2.45% | $4.03 | -4.95% | -11.82% | -21.44% |
| GHC | Graham Holdings Co | 2.37% | $1203.26 | +0.38% | +2.57% | +5.23% |
| LOPE | Grand Canyon Education Inc | 2.31% | $161.58 | +0.09% | +1.11% | +6.82% |
| PFE | Pfizer Inc | 2.25% | $29.58 | +0.48% | +4.60% | +6.94% |
| LRN | Stride Inc | 2.12% | $82.39 | -0.95% | -3.74% | +4.42% |